Shun Lu, Byoung Chul Cho, Ziming Li, Bin Yang, Vanesa Gregorc, Lin Wu, Jun Zhao, Herbert H. Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Janet Chen, Jing Zhang, Melissa Lynne Johnson, Allison Wang, Ben Solomon, George Zhi Jian Chen, Tony S.K. Mok. "Elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor, as first-line therapy for
                    <i>KRAS</i>
                    G12C mutation–positive non–small cell lung cancer (NSCLC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.8511